malOMVax
malOMVax
is a Malaria vaccine candidate conceived on the mOMV platform
Under development by AchilleS Achilles Vaccines Srl in cooperation with the the National Institute of Molecular Genetics, Milano, Italy
malOMVax
AchilleS Vaccines uses multidisciplinary, combinatorial, innovative science towards malaria vaccine development. The malOMVax project exploits advanced clinical-immunology-guided reverse vaccinology, combined to the flexible mOMV platform, to deliver antigens able to induce protective immunity against a broad range of Plasmodium parasites.
AchilleS’ approach maximizes the chances of developing a novel mOMV-based malaria vaccine capable of eliciting strong immunity against multiple parasite antigens and providing long-lasting protection.
AchilleS Vaccines is a Siena-based biotech company specialising in research on malaria, antimicrobial resistance and, lately, COVID-19. The company follows an innovative approach to malaria vaccine development while also offering reverse vaccinology-based therapeutic and preventive interventions against COVID-19.
Achilles Vaccine’s modified Bacterial Outer Membrane Vesicles (mOMV) are a highly flexible vaccine platform, with which a new response to the ancient need for multi-antigen malaria vaccine can be realistically done. OMVs are designed as safe and highly immunogenic in humans, even enabling fine-tuning of elicited immunity. OMV-based malaria vaccine will contain a variety of antigens, uniquely providing multivalent broad coverage against all the phases of the diseases, pre-, intra-erythrocytic and transmission.
The selection of antigens will be guided by clinical-immunology and infection neutralization screenings applying the most advanced techniques of reverse vaccinology methodologies, a fully unbiased approach for identifying all protective malaria antigens. Achilles Vaccines therefore aims to offer a completely new well tolerated malaria vaccine prototype, expected to outperform currently tested single-antigens.